论文部分内容阅读
糖尿病是一种常见的全身性慢性代谢性疾病。在临床上将胰岛分泌功能的情况分为胰岛素依赖型和非胰岛素依赖型两类。格列吡嗪为治疗非胰岛素依赖型糖尿病的口服降糖药,是磺酰脲类的第二代产品。它以疗效确切、副作用小,并有调节血脂,降低血小板凝聚,增加血纤维蛋白溶解活性等作用,而成为该类药品中较为优秀的品种。这一品种是意大利爱宝药厂开发上市的,商品名“美吡哒”,已收入英国药典88版,并被美国FDA批准,畅销于欧美市场。目前国内市场亦销售该厂的进口产品。
Diabetes is a common systemic chronic metabolic disease. Clinically, pancreatic islet function is divided into two types: insulin-dependent and non-insulin-dependent. Glipizide is an oral hypoglycemic agent for the treatment of non-insulin-dependent diabetes and is the second generation of sulfonylureas. It has the exact effect, side effects, and regulate blood lipids, reduce platelet aggregation, increase the role of fibrinolytic activity, and become the more outstanding varieties of such drugs. This variety is developed and marketed by Alipay Pharmaceuticals of Italy under the trade name of “Pyridoxine” and has been included in the 88th edition of the British Pharmacopoeia. It has been approved by the U.S. FDA and sold well in the European and American markets. Currently the domestic market also sells the factory’s imported products.